ERBB2

Chr 17AR

erb-b2 receptor tyrosine kinase 2

Also known as: CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19, NEU, NGL

This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized. [provided by RefSeq, Jul 2008]

Primary Disease Associations & Inheritance

?Visceral neuropathy, familial, 2, autosomal recessiveMIM #619465
AR
Adenocarcinoma of lung, somaticMIM #211980
Gastric cancer, somaticMIM #613659
Glioblastoma, somaticMIM #137800
Ovarian cancer, somaticMIM #167000
UniProtGlioma
UniProtLung cancer
12
Active trials
466
ClinVar variants
13
Pathogenic / LP
3.2
Missense Z· constrained
0.40
LOEUF
10
Pubs (2 yr)
Clinical SummaryERBB2
Population Constraint (gnomAD)
Constrained for loss-of-function variants (OE-LoF 0.27) despite low pLI — interpret in context.
📋
ClinVar Variants
13 Pathogenic / Likely Pathogenic· 272 VUS of 466 total submissions
💊
Clinical Trials
12 active or recruiting trials — potential therapeutic options may be available
📖
GeneReview available — ERBB2
Authoritative clinical overview · Recommended first read
Open GeneReview ↗
Some data sources returned errors (1)

ensembl: TimeoutError: The operation was aborted due to timeout

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Missense constrained — critical functional residues
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
0.40LOEUF
pLI 0.006
Z-score 5.57
OE 0.27 (0.180.40)
Moderately constrained

More LoF-intolerant than ~75% of genes

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
3.25Z-score
OE missense 0.67 (0.620.72)
510 obs / 762.5 exp
Constrained

Highly missense-constrained (top ~0.1%)

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.27 (0.180.40)
00.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.0.67 (0.620.72)
00.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.0.99
01.21.6
LoF obs/exp: 18 / 67.3Missense obs/exp: 510 / 762.5Syn Z: 0.15

ClinVar Variant Classifications

466 submitted variants in ClinVar

Classification Summary

Pathogenic11
Likely Pathogenic2
VUS272
Likely Benign159
Benign18
Conflicting4
11
Pathogenic
2
Likely Pathogenic
272
VUS
159
Likely Benign
18
Benign
4
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
2
3
6
0
11
Likely Pathogenic
0
0
2
0
2
VUS
9
239
20
4
272
Likely Benign
1
7
66
85
159
Benign
0
1
7
10
18
Conflicting
4
Total1225010199466

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

ERBB2 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

?Visceral neuropathy, familial, 2, autosomal recessive

MIM #619465

Molecular basis of disorder known

Autosomal recessive

Adenocarcinoma of lung, somatic

MIM #211980

Molecular basis of disorder known

Gastric cancer, somatic

MIM #613659

Molecular basis of disorder known

Glioblastoma, somatic

MIM #137800

Molecular basis of disorder known

Ovarian cancer, somatic

MIM #167000

Molecular basis of disorder known

Clinical Literature
Landmark / reviewRecent case evidence
Full-Text Mentions
NLP-detected gene mentions in article bodies · via PubTator3
PubTator3
Top 10 full-text resultsSearch PubTator3 ↗

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Advanced Breast Cancer

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

RECRUITING
NCT06380751Phase PHASE3AstraZenecaStarted 2024-08-01
Saruparib (AZD5305)CamizestrantAbemaciclib
Advanced or Metastatic Breast Cancer (BC)

Trans-RosaLEE Study: a Biomarker-directed, Translational Study

ACTIVE NOT RECRUITING
NCT05529862Phase NAInstitut Paoli-CalmettesStarted 2023-06-20
Pre-treatment biopsyPost treatment biopsyPre treatment blood sampling
Breast CancerBreast NeoplasmsHormone Receptor Positive Tumor

Establishment of Molecular Profiling for Individual Clinical Routine Treatment Decision in Early Breast Cancer

ACTIVE NOT RECRUITING
NCT03904173Oslo University HospitalStarted 2018-10-29
Multi-parameter tests
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

RECRUITING
NCT05319873Phase PHASE1, PHASE2Jonsson Comprehensive Cancer CenterStarted 2022-04-07
CarboplatinDocetaxelFulvestrant
Ovarian CancerHER2

Efficacy and Safety of Distamab Vedotin Combined With Carboplatin for Advanced Ovarian Cancer in the First Line Treatment

RECRUITING
NCT07285941Phase PHASE2Zhejiang Cancer HospitalStarted 2025-01-04
RC48 + Carboplatin
Liver CancerLung CancerBreast Cancer

Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors

RECRUITING
NCT04842812Phase PHASE1Second Affiliated Hospital of Guangzhou Medical UniversityStarted 2021-01-01
TILs and CAR-TILs targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, or B7-H3
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8HER2-Negative Breast Carcinoma

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

RECRUITING
NCT06058377Phase PHASE3National Cancer Institute (NCI)Started 2023-11-27
Biospecimen CollectionCyclophosphamideDoxorubicin
Cancer

Pharmacokinetic Boosting of Olaparib to Improve Exposure, Tolerance and Cost-effectiveness

RECRUITING
NCT05078671Phase PHASE4Radboud University Medical CenterStarted 2021-12-15
OlaparibCobicistat
PIK3CA MutationSolid Tumor, AdultHER2-negative Breast Cancer

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

RECRUITING
NCT05216432Phase PHASE1Relay Therapeutics, Inc.Started 2021-12-08
RLY-2608FulvestrantPalbociclib 125mg
Breast Cancer

An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy

RECRUITING
NCT07117630Phase PHASE2Fudan UniversityStarted 2025-09-25
L-Ornithine L-AspartateCDK4/6 inhibitorFulvestrant
Breast Cancer

Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes

NOT YET RECRUITING
NCT07187752Phase NAShandong Cancer Hospital and InstituteStarted 2025-09-30
TrastuzumabPertuzumabChemotherapy
Locally Advanced Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8

Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation

RECRUITING
NCT07012031Phase PHASE1, PHASE2National Cancer Institute (NCI)Started 2026-08-07
Biopsy ProcedureBiospecimen CollectionComputed Tomography